Pernilla Danielsson, Resthie R Putri, Claude Marcus, Emilia Hagman
Journal: Scientific reports 2023;13(1):18200
PMID: 37875559
Weight loss regimes rely on creating an energy deficit—where energy intake is lower than energy expenditure. However, this approach proves challenging for many individuals to effectively put into practice. In humans, individuals with overweight exhibit a decreased gut bacterial diversity and an altered composition of bacterial species. The aim of this study was to assess the impact of the probiotic compound AB001 on weight loss among individuals with overweight. This study was a single-centre, double-blind, three parallel group, block randomised, placebo-controlled trial. Participants were randomly assigned (1:1:1) to single dose probiotics, double dose probiotics, or placebo. Results showed that during the initial 3-month double-blinded placebo-controlled phase, no difference in weight was observed between the groups. During the second phase, individuals who were administrated a high dose probiotic, i.e. first double and then triple dose, experienced a statistically significant weight reduction from their baseline of approximately 2 kg. Authors concluded that their findings provide evidence that a double and triple dose of the probiotic compound AB001 is well tolerated and can be consumed safely by adults.
The aim was to assess the weight-reducing effects of various doses of a probiotic dietary supplement and evaluate the tolerance and safety of increased dosage. A 3-month double-blinded, randomized, placebo-controlled trial, followed by a 3-month open phase, was conducted at Karolinska Institutet, Sweden. The probiotic compound AB001 was tested at two doses (single and double) and compared with placebo during the blinded phase, and at triple dose during the open phase. Eighty-one volunteers, 18-45 years old, with overweight were included. The primary outcome was change in weight. Secondary outcomes were changes in; BMI, waist circumference, blood pressure, blood lipids, glucose metabolism, liver enzymes, vitamin levels, and bowel habits. After 3 months (n = 81), no difference in weight, BMI, waist circumference, blood pressure, or biomarkers were observed between the groups. Forty-five individuals continued with triple dose. The group with initial single dose decreased 0.93 ± 4.73 kg (p = 0.34), and the group with double dose initially decreased 1.93 ± 3.70 kg (p = 0.027). Reported changes in bowel habits and gastro-intestinal problems were similar for all doses. The results indicate that a long-term use of at least double dose AB001 may be more beneficial for weight loss than lower doses. However, in the double blinded phase, no differences between groups were found. The probiotic compound AB001 was well tolerated and can safely be used up to double dose for 90 days followed by triple dose for 90 days.Trial registration: Clinicaltrial.gov NCT04897698, registered on 21 May 2021.
© 2023. Springer Nature Limited.
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.